PharmTech Drug Digest 11.20
News|Articles|June 4, 2013

Sanofi Ends Development of Two Phase III Drugs

-

Sanofi has discontinueddevelopment of two investigational drugs in Phase III development, iniparib, a drug to treat non-small cell lung cancer, and otamixaban, an anticoagulant, based on recent clinical results. Sanofi will take an after-tax change of $285 million for iniparib.


Related to this article

Green Chemistry Supply and Demand in Sustainable Pharma
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.